文献速递鼻科

内镜下鼻窦手术用于复发性急性鼻窦炎:一项随机临床试验

Endoscopic Sinus Surgery for Recurrent Acute Rhinosinusitis: A Randomized Clinical Trial.
PubMed 文献 · JAMA Otolaryngol Head Neck Surg · 2026-01-01

这项开放标签随机临床试验纳入59例保守治疗不足的复发性急性鼻窦炎成人患者,比较内镜下鼻窦手术联合药物治疗与单纯药物治疗。术后6个月手术组SNOT-22评分改善较对照组多22.41分(95%CI 13.67-31.10),提示内镜下鼻窦手术可改善生活质量且无重大并发症。

要点

  • 对保守治疗不足的复发性急性鼻窦炎成人,内镜下鼻窦手术联合药物较单纯药物显著改善6个月SNOT-22评分。
  • 手术组仅4例因手术并发症接受干预(3例感染,1例粘连伴鼻中隔穿孔)。
  • 单纯保守治疗对复发性急性鼻窦炎无临床意义的效果。

核心结论

  • 在复发性急性鼻窦炎成人中,内镜下鼻窦手术联合药物治疗较单纯药物治疗在6个月随访时改善患者相关结局。
  • 保守治疗对复发性急性鼻窦炎无临床意义的效果。
  • 内镜下鼻窦手术是有效治疗且无重大问题。

研究设计与样本

  • 开放标签随机临床试验,2个平行组,随访6个月,于2020年5月至2024年6月在奥卢大学医院耳鼻咽喉科招募患者。
  • 共纳入59例患者(平均[SD]年龄40[14]岁;52例女性[88%]),手术组30例,保守组29例。
  • 纳入标准为成人医师诊断的复发性急性鼻窦炎,过去6个月内至少发作3次、过去1年内4次或连续3年每年2次,且保守治疗症状缓解不足。
  • 主要结局为基线至6个月随访时SNOT-22评分变化的组间差异,采用意向性治疗分析。

主要发现

  • 手术组较单纯药物组6个月SNOT-22评分平均变化更大,差异为22.41分(95%CI 13.67-31.10分)。
  • 次要结局的符合方案分析大多支持主要发现。
  • 仅4例患者因手术并发症接受干预(3例感染,1例粘连伴鼻中隔穿孔)。

关键数值与推荐

  • 纳入标准:过去6个月内至少3次、过去1年内4次或连续3年每年2次医师诊断的复发性急性鼻窦炎发作,且保守治疗症状缓解不足。
  • 主要结局:基线至6个月SNOT-22评分变化的组间差异为22.41分(95%CI 13.67-31.10分),利于手术组。
  • 手术并发症干预:4例(3例感染,1例粘连伴鼻中隔穿孔)。

临床怎么用

  • 对保守治疗不足的复发性急性鼻窦炎成人,可考虑内镜下鼻窦手术以改善生活质量。
  • 术前应告知患者手术并发症风险低但存在,如感染和粘连。
  • 单纯保守治疗对复发性急性鼻窦炎可能无临床意义的效果。

局限性

  • 开放标签设计可能引入偏倚。
  • 样本量较小(59例),随访仅6个月。
  • 单中心研究,外推性受限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Recurrent acute rhinosinusitis (RARS) decreases quality of life. The effects of endoscopic sinus surgery (ESS) in RARS are understudied. OBJECTIVE: To compare the quality of life between patients with RARS who had surgery and medical treatment vs medical treatment alone. DESIGN, SETTING, AND PARTICIPANTS: This is an open-label randomized clinical trial with 2 parallel groups with a 6-month follow-up. Patients referred to Oulu University Hospital Otolaryngology Clinic between May 2020 and June 2024 were recruited to participate in the trial. Inclusion criteria were adults with physician-diagnosed RARS episodes occurring at least 3 times during the past 6 months, 4 times during the past year, or twice per year for 3 consecutive years. Conservative treatment had been insufficient for symptom relief. Data collection and analyses were planned before commencing recruitment. Data collection was performed from May 2020 to December 2024, and analysis from January 2025 to January 2026. INTERVENTIONS: The operative group received ESS and medical treatment, and the conservative group received medical treatment alone. MAIN OUTCOMES AND MEASURES: The main outcome was the difference between groups in mean SinoNasal Outcome Test 22 (SNOT-22) score change from baseline to a 6-month follow-up. The SNOT-22 questionnaire measures rhinosinusitis-related quality of life. Sinonasal symptoms, number of health care visits, antibiotic courses, absences from work or study, and the adverse effects of operative treatment were also studied. RESULTS: A total of 59 patients (mean [SD] age, 40 [14] years; 52 women [88%]) were recruited, 30 in the operative and 29 in the conservative group. Intention-to-treat analysis of the primary outcomes was performed. The mean SNOT-22 score change from baseline to 6 months was greater after ESS compared to medical treatment only (difference, 22.41 points (95% CI, 13.67-31.10 points). Per-protocol analyses of secondary outcomes supported the primary findings for the most part. Only 4 patients received intervention for an operative complication (3 infections, 1 synechia with septal perforation). CONCLUSIONS AND RELEVANCE: In this randomized clinical trial, ESS improved patient-related outcomes at a 6-month follow-up in adults with RARS. Conservative treatment had no clinically meaningful effect. These results suggest that ESS is an effective treatment without major problems. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04241016.

来源:JAMA Otolaryngol Head Neck Surg,查看原文。版权归原作者所有。

引用

  1. Kaski H, Alakärppä A, Laajala A, et al. Endoscopic Sinus Surgery for Recurrent Acute Rhinosinusitis: A Randomized Clinical Trial. JAMA Otolaryngol Head Neck Surg. 2026. PMID: 42313411. doi:10.1001/jamaoto.2026.1537

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。